Aprea Therapeutics Inc (APRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.91M
Last updated: Nov 17, 2026 at 11:02 AM ET
Aprea Therapeutics Inc (APRE) Earnings: Report Dates and Results
Aprea Therapeutics (APRE) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Aprea Therapeutics reported EPS of -$0.09, below the -$0.08 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
APRE has an expected report date of Mar 15, 2027.
Earnings History
Of the 29 quarters below that had an estimate, APRE beat 18 and missed 11. The widest gap in the table came in the quarter ended Jun 30, 2022, when EPS landed 216.61% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.09 | -$0.08 | -$0.09 - -$0.07 | -12.50% | Miss | N/A | 3 | 0 up, 0 down | Nov 4, 2026 | N/A |
| Jun 30, 2026 | -$0.07 | -$0.22 | -$0.23 - -$0.21 | +68.18% | Beat | N/A | 2 | 0 up, 0 down | Aug 12, 2026 | N/A |
| Mar 31, 2026 | -$0.22 | -$0.23 | -$0.23 - -$0.23 | +4.35% | Beat | N/A | 1 | 0 up, 0 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.32 | -$0.36 | -$0.37 - -$0.35 | +11.11% | Beat | N/A | 2 | 0 up, 0 down | Mar 16, 2026 | $3337 |
| Sep 30, 2025 | -$0.47 | -$0.34 | N/A | -38.24% | Miss | N/A | 1 | 0 up, 0 down | Nov 12, 2025 | $1848 |
| Jun 30, 2025 | -$0.53 | -$0.71 | -$0.71 - -$0.71 | +25.35% | Beat | N/A | 1 | 0 up, 0 down | Aug 12, 2025 | $118111 |
| Mar 31, 2025 | -$0.66 | -$1.00 | N/A | +34.39% | Beat | N/A | 2 | 1 up, 0 down | May 14, 2025 | $162463 |
| Dec 31, 2024 | -$0.49 | -$0.54 | -$0.54 - -$0.54 | +9.26% | Beat | N/A | 1 | 1 up, 0 down | Mar 25, 2025 | $205817 |
| Sep 30, 2024 | -$0.64 | -$0.74 | -$0.87 - -$0.62 | +13.51% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | $354621 |
| Jun 30, 2024 | -$0.58 | -$0.60 | -$0.69 - -$0.58 | +3.33% | Beat | N/A | 2 | 0 up, 0 down | Aug 12, 2024 | $561574 |
| Mar 31, 2024 | -$0.67 | -$0.80 | -$0.80 - -$0.75 | +16.25% | Beat | N/A | 2 | 0 up, 0 down | May 14, 2024 | $380569 |
| Dec 31, 2023 | -$0.92 | -$0.77 | -$1.20 - -$0.19 | -19.48% | Miss | N/A | 3 | 0 up, 0 down | Mar 26, 2024 | $14075 |
| Sep 30, 2023 | -$0.86 | -$1.04 | -$1.33 - -$1.04 | +17.31% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2023 | $319468 |
| Jun 30, 2023 | -$0.87 | -$1.38 | -$1.47 - -$1.38 | +36.96% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | $249688 |
| Mar 31, 2023 | -$1.34 | -$0.82 | -$2.19 - -$0.82 | -63.41% | Miss | N/A | 2 | 0 up, 0 down | May 15, 2023 | N/A |
| Dec 31, 2022 | -$0.92 | -$3.08 | -$4.04 - -$2.40 | +70.13% | Beat | N/A | 3 | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$2.40 | -$1.60 | N/A | -50.00% | Miss | N/A | 2 | 0 up, 0 down | Nov 9, 2022 | N/A |
| Jun 30, 2022 | -$19.63 | -$6.20 | N/A | -216.61% | Miss | N/A | 2 | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$7.20 | -$7.60 | -$7.60 - -$7.60 | +5.26% | Beat | N/A | 1 | 0 up, 0 down | May 16, 2022 | N/A |
| Dec 31, 2021 | -$7.20 | -$8.80 | -$8.80 - -$8.80 | +18.18% | Beat | N/A | 3 | 0 up, 0 down | Mar 15, 2022 | N/A |
| Sep 30, 2021 | -$9.00 | -$9.05 | -$9.80 - -$8.00 | +0.55% | Beat | N/A | 4 | 2 up, 0 down | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$9.60 | -$9.35 | -$10.20 - -$8.20 | -2.67% | Miss | N/A | 4 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$9.20 | -$9.85 | -$12.40 - -$8.00 | +6.60% | Beat | N/A | 4 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$14.60 | -$12.85 | -$13.80 - -$10.60 | -13.62% | Miss | N/A | 4 | N/A | Mar 16, 2021 | N/A |
| Sep 30, 2020 | -$11.60 | -$15.20 | -$16.60 - -$14.00 | +23.68% | Beat | N/A | 5 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$15.60 | -$12.05 | -$13.00 - -$11.60 | -29.46% | Miss | N/A | 4 | N/A | Aug 11, 2020 | N/A |
| Mar 31, 2020 | -$9.00 | -$11.35 | -$12.80 - -$9.60 | +20.70% | Beat | N/A | 4 | N/A | May 15, 2020 | N/A |
| Dec 31, 2019 | -$12.80 | -$8.00 | -$8.40 - -$7.60 | -60.00% | Miss | N/A | 3 | N/A | Mar 26, 2020 | N/A |
| Sep 30, 2019 | -$105.80 | -$78.87 | -$117.60 - -$12.60 | -34.14% | Miss | N/A | 3 | N/A | Oct 3, 2019 | N/A |
| Jun 30, 2019 | -$0.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 28, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.98, after -$2.38 the year before. It was -$118.91 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.98 | N/A |
| Dec 31, 2024 | -$2.38 | N/A |
| Dec 31, 2023 | -$3.99 | N/A |
| Dec 31, 2022 | -$30.15 | N/A |
| Dec 31, 2021 | -$35.00 | N/A |
| Dec 31, 2020 | -$50.80 | N/A |
| Dec 31, 2019 | -$118.91 | N/A |
Frequently Asked Questions About APRE
When is Aprea Therapeutics's next earnings date?
Aprea Therapeutics's next earnings report is expected for Mar 15, 2027.
Did APRE beat earnings estimates last quarter?
No. Aprea Therapeutics reported EPS of -$0.09 for the quarter ended Sep 30, 2026, below the -$0.08 estimate by 12.50%.
What EPS do analysts expect from APRE next quarter?
The consensus EPS estimate for Aprea Therapeutics for the quarter ending Dec 31, 2026 is -$0.09 from 6 analysts, with estimates from -$0.11 to -$0.05.
How often does APRE beat earnings estimates?
Aprea Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +12.74%.
APRE pages: Overview, Earnings, Forecast, Financials, Competitors